Loading
A phase 1/2 trial of JSKN016, Capecitabine, Eribulin and Pembrolizumab in advanced solid tumours, run by Jiangsu Alphamab Biopharmaceuticals Co., Ltd, now recruiting.
Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer is a phase 1/2 interventional study registered as NCT06942234 by Jiangsu Alphamab Biopharmaceuticals Co., Ltd, with 180 participants planned, started 2025-06-01 and due to reach its primary completion in 2027-06-30. Interventions recorded: JSKN016, Capecitabine, Paclitaxel (albumin bound), Eribulin and Pembrolizumab.
Shares Alphamab Oncology, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Eribulin, Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Eribulin, Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Capecitabine, Metastatic cancer (cancer that has spread), Pembrolizumab and the tag pipeline.
Shares Eribulin, Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Eribulin, Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Eribulin, Capecitabine and the tag pipeline.
Shares Eribulin, Capecitabine and the tag pipeline.